TFS HealthScience, a Sweden-based global contract research organisation, announced Monday that it is expanding into Israel to improve its offerings and geographic reach to support increasing customer demand.
The development includes a formalised agreement with the former external partner of TFS HealthScience in the Middle East, GCP Clinical Studies (GCP), Israel's leading contract research organisation (CRO), and clinical research training centre.
This agreement will further grow TFS HealthScience's expertise in the specialty therapeutic areas of ophthalmology, oncology and haematology, dermatology, immunology and inflammatory disease, and internal medicine and neuroscience.
Luke Gill, head of Clinical Development Solutions at TFS HealthScience, said, '2023 continues to be a year of growth for the company as we announce our formal expansion into Israel. We are confident that this expansion will bring immense value to our clients and ultimately support the development of more lifesaving therapies.'
Genelux secures FDA Fast Track designation for Olvi-Vec in ovarian cancer
GSK reports positive results in DREAMM-7 Phase III trial for blenrep in multiple myeloma
Hemogenyx Pharmaceuticals expands CBR platform for cancer treatment
DxVx to conduct own clinical trials of OVM-200
Innovent's IBI351 New Drug Application receives Chinese regulatory approval
EirGenix's trastuzumab biosimilar medicine receives European marketing authorisation
Innovent and AnHeart announce acceptance of NDA for taletrectinib in China